Foresight Co-Lab
Beyond
Ozempic
Planning for the Next Five Years
Beyond Ozempic: Planning for the Next Five Years of AOMs
Ozempic and other GLP-1 medications have taken the marketplace by storm. Moving forward, their impact will be felt across a wide range of industries as both clinical and off-label uses (e.g., cosmetic weight loss) are expected to grow rapidly. In fact, some project the global market for these drugs will rise from about $20 billion in 2022 to more than $100 billion in 2030.
But business leaders don’t need market forecasts to know that anti-obesity medications (AOMs) will be a gamechanger. What they need is a clear-eyed view of the future AOM landscape and a deeper understanding of what the downstream impacts will be for their categories and businesses.
To address this need, Kantar invites you to take part in Beyond Ozempic: Planning for the Next Five Years of AOMs, a multi-client research project exploring scenarios for the future of this dynamic space.
These scenarios deliver clarity about the future of AOMs and, more importantly, how these drugs might impact the lives of consumers and the fortunes of brands and businesses well beyond the health sector.
Co-Lab Clients receive:
An introductory call to orient you to the project, meet the Kantar team that worked on this project, and plan the research readout.
The Beyond Ozempic Co-Lab report, which includes an analysis of key drivers of change and a set of five scenarios for the 3-5 year future of the AOM landscape.
A 60-minute readout of the research to socialize the Beyond Ozempic scenario report and discuss implications with your organization.
Co-Lab clients may choose to add:
– A full-day action planning workshop to stress test current portfolio and strategies against this future view.
– Quantitative data and insights from Kantar’s ongoing survey work into the behaviors and attitudes of consumers who use GLP-1s.